Semisynthetic bioflavonoid (derivative of routine) of the class of benzopyrans, has P-vitamin activity, it has venotonic, angioprotective, anti-inflammatory and anti-edematous effect, reduces permeability and fragility of capillaries.
Its pharmacodynamic properties are associated with the participation of trouxerutin bioflavonoids in oxidation-reduction processes and inhibition of hyaluronidase. By suppressing hyaluronidase, troxerutin stabilizes the hyaluronic acid of cell membranes and reduces their permeability. It has antioxidant activity, which prevents oxidation of ascorbic acid, adrenaline and lipids. In addition, it reduces the permeability and fragility of capillaries, prevents damage to the basal membrane of endothelial cells when various factors influence it. Troxerutin increases the density of the vascular wall, reduces exudation of the liquid part of the plasma and diapedesis of blood cells. Reduces exudative inflammation in the vascular wall, reducing the adhesion of platelets to its surface. Inhibits aggregation and increases the degree of erythrocyte deformation.
The use of troxerutin is possible, both at the initial and late stages of treatment of chronic venous insufficiency, it is possible to use complex treatment as one of the components. Troxerutin reduces puffiness and a feeling of heaviness in the legs, reduces the intensity of pain and seizures, improves trophic tissue. Troxerutin facilitates the symptoms associated with hemorrhoids (pain, exudation, itching, bleeding).
Due to the effect on the permeability and resistance of the capillary walls troxerutin helps slow the progression of diabetic retinopathy. The effect of troxerutin on the rheological properties of the blood contributes to the prevention of the development of microtrombosis of the retinal vessels.